AR123147A1 - Formulaciones de compuestos trifenilcalcilíticos - Google Patents
Formulaciones de compuestos trifenilcalcilíticosInfo
- Publication number
- AR123147A1 AR123147A1 ARP210102174A ARP210102174A AR123147A1 AR 123147 A1 AR123147 A1 AR 123147A1 AR P210102174 A ARP210102174 A AR P210102174A AR P210102174 A ARP210102174 A AR P210102174A AR 123147 A1 AR123147 A1 AR 123147A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- combination
- represented
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000007916 tablet composition Substances 0.000 abstract 3
- 201000003974 autosomal dominant hypocalcemia Diseases 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061050P | 2020-08-04 | 2020-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123147A1 true AR123147A1 (es) | 2022-11-02 |
Family
ID=77431430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102174A AR123147A1 (es) | 2020-08-04 | 2021-08-04 | Formulaciones de compuestos trifenilcalcilíticos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220040112A1 (enExample) |
| EP (1) | EP4192438A1 (enExample) |
| JP (2) | JP7827696B2 (enExample) |
| KR (1) | KR20230106582A (enExample) |
| CN (1) | CN116648243A (enExample) |
| AR (1) | AR123147A1 (enExample) |
| AU (1) | AU2021320147B2 (enExample) |
| BR (1) | BR112023002107A2 (enExample) |
| CA (1) | CA3188044A1 (enExample) |
| IL (1) | IL300285A (enExample) |
| MX (1) | MX2023001438A (enExample) |
| TW (1) | TWI924683B (enExample) |
| WO (1) | WO2022031666A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116648243A (zh) | 2020-08-04 | 2023-08-25 | 柯西立提克斯疗法有限公司 | 三苯基钙敏感化合物的制剂 |
| MX2023003129A (es) * | 2020-09-18 | 2023-08-04 | Calcilytix Therapeutics Inc | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). |
| WO2024160842A1 (en) | 2023-01-30 | 2024-08-08 | Medizinische Universität Wien | Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050460A1 (es) | 2003-04-23 | 2005-07-08 | Japan Tobacco Inc | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
| SG174564A1 (en) * | 2009-03-26 | 2011-10-28 | Japan Tobacco Inc | Process for producing carboxylic acid compound |
| ES2900353T3 (es) * | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| GB201217330D0 (en) * | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| BR112020013073A2 (pt) | 2017-12-29 | 2020-12-01 | Biomarin Pharmaceutical Inc. | composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo |
| WO2021029517A1 (en) | 2019-08-13 | 2021-02-18 | Dongguk University Industry-Academic Cooperation Foundation | Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same |
| GB201918586D0 (en) * | 2019-12-17 | 2020-01-29 | Patterson James | Engineered platelets for targeted delivery of a therapeutic agent |
| CN116648243A (zh) | 2020-08-04 | 2023-08-25 | 柯西立提克斯疗法有限公司 | 三苯基钙敏感化合物的制剂 |
| MX2023003129A (es) | 2020-09-18 | 2023-08-04 | Calcilytix Therapeutics Inc | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). |
-
2021
- 2021-08-03 CN CN202180066180.1A patent/CN116648243A/zh active Pending
- 2021-08-03 CA CA3188044A patent/CA3188044A1/en active Pending
- 2021-08-03 MX MX2023001438A patent/MX2023001438A/es unknown
- 2021-08-03 BR BR112023002107A patent/BR112023002107A2/pt unknown
- 2021-08-03 JP JP2023507979A patent/JP7827696B2/ja active Active
- 2021-08-03 AU AU2021320147A patent/AU2021320147B2/en active Active
- 2021-08-03 WO PCT/US2021/044295 patent/WO2022031666A1/en not_active Ceased
- 2021-08-03 KR KR1020237007456A patent/KR20230106582A/ko active Pending
- 2021-08-03 IL IL300285A patent/IL300285A/en unknown
- 2021-08-03 EP EP21758555.3A patent/EP4192438A1/en active Pending
- 2021-08-03 US US17/392,720 patent/US20220040112A1/en not_active Abandoned
- 2021-08-04 AR ARP210102174A patent/AR123147A1/es unknown
- 2021-08-04 TW TW110128669A patent/TWI924683B/zh active
-
2023
- 2023-06-29 US US18/216,536 patent/US12357576B2/en active Active
-
2026
- 2026-02-26 JP JP2026029931A patent/JP2026086851A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023002107A2 (pt) | 2023-03-07 |
| CN116648243A (zh) | 2023-08-25 |
| US12357576B2 (en) | 2025-07-15 |
| EP4192438A1 (en) | 2023-06-14 |
| MX2023001438A (es) | 2023-06-15 |
| JP7827696B2 (ja) | 2026-03-10 |
| TW202220642A (zh) | 2022-06-01 |
| AU2021320147B2 (en) | 2026-07-30 |
| US20220040112A1 (en) | 2022-02-10 |
| CA3188044A1 (en) | 2022-02-10 |
| JP2026086851A (ja) | 2026-05-26 |
| KR20230106582A (ko) | 2023-07-13 |
| IL300285A (en) | 2023-04-01 |
| JP2023536667A (ja) | 2023-08-28 |
| WO2022031666A1 (en) | 2022-02-10 |
| US20240074978A1 (en) | 2024-03-07 |
| AU2021320147A1 (en) | 2023-03-30 |
| TWI924683B (zh) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| MX2022012306A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| MX2021005898A (es) | Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| AR118805A2 (es) | Terapia de combinación para el tratamiento de la diabetes | |
| DOP2021000045A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inihibidores de ccr6 | |
| CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
| CL2024004060A1 (es) | Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CO2019010029A2 (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer | |
| MX2024003028A (es) | Derivados de 6 aza quinolina y usos relacionados. | |
| PE20241174A1 (es) | Compuestos de arsenico de fenilo oxidado halogenado y sus aplicaciones | |
| MX2024003399A (es) | Derivados de piridazinil-amino como inhibidores del receptor del factor de crecimiento transformante beta tipo i (alk5). | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX2023001438A (es) | Formulaciones de compuestos calciliticos de trifenilo. | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| PE20252162A1 (es) | Derivados de benzimidazol ciclico como inhibidores de cgas | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| PE20040906A1 (es) | Derivados morfolinicos como agonistas de dopamina | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica |